Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 440

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Bacterial superantigens

Open access
PROFT, T, FRASER, J D·2003·Clinical and Experimental Immunology

Abstract

Superantigens (SAgs) are the most powerful T cell mitogens ever discovered. Concentrations of less than 0·1 pg/ml of a bacterial superantigen are sufficient to stimulate the T lymphocytes in an uncontrolled manner resulting in fever, shock and death [1–3]. SAgs bind, as intact molecules to the class II major histocompatibility complex (MHC) antigens expressed on professional antigen presenting cells (APCs) outside the peptide-binding groove then sequentially bind the T cell receptor (TcR) via the variable region of the TcR β-chain [3–6]. Every SAg binds a subset of TcR Vβ domains and as the number of different Vβ regions in the human T cell repertoire is restricted to approximately 50, comprising about 24 major types of Vβ elements, a substantial number of T cells are activated by SAgs. This can be as high as 20% compared with only 1 in 105−106 naive T cells that are responsive to conventional peptide antigen. This results in massive systemic release of pro-inflammatory cytokines, such as tumour necrosis factor-alpha (TNF-α) and interleukin-beta (IL-1β), and T cell mediators, such as IL-2, which can lead to fever and shock [3,5,7,8]. Over the last 4 years the number of known bacterial SAgs has increased sharply, due mainly to various microbial genome sequencing projects [9–14]. There are now 41 bacterial SAgs described in the literature (Table 1) and the number is growing steadily. In addition, a new family of SAg-related proteins has been identified in Staphylococcus aureus that show sequence and structural homology to the ‘classical’ SAgs, but appear to have a quite different role. This review provides a summary of the field to date with some of the more recent discoveries that shed light on the how superantigens are able to trigger such strong T cell responses and the diseases related to SAg intoxication. Functional properties of superantigens and their associated diseases Functional properties of superantigens and their associated diseases SAgs are characterized by their ability to bind both MHC class II molecules and T cell receptors [5,6]. This occurs in a sequential fashion. The sole purpose of SAgs appears to be to bring these two critical molecules together in order to activate as many T cells as possible. The net result is the release of a large and sudden bolus of cytokines which causes the acute condition toxic shock [3,5,7,8] The histocompatibility class II molecule, despite its polymorphism, is the principal cell receptor for all SAgs but the affinity for MHC class II varies depending on the class II molecule and the SAg [15–17]. All SAgs examined so far display higher affinities towards human MHC class II molecules than mouse class II, which explains partly why SAgs are several orders of magnitude more potent on human T cells than mouse T cells. A variety of binding modes exist to both MHC class II and TcR (described in more detail below) which indicates the lengths that the bacteria have gone to target these two critical molecules of the adaptive immune response. The first bacterial SAg was isolated in the late 1960s by Bergdoll and coworkers as a secreted toxin of S. aureus and was named staphylococcal enterotoxins A (SEA) for its potent enterotoxic properties. The staphylococcal enterotoxins (SE) are the causative agent in staphylococcal food poisoning and induce vomiting and diarrhoea within 1–2 h following ingestion. The mitogenic activity of SEs was discovered many years later, but the term ‘superantigen’ was not coined until 1989 when Marrack and coworkers found that the mitogenic activity was a result of a massive expansion of T cells that all shared the same T cell receptor Vβ chain domains [2]. Today, 18 different SEs have been described in the literature (Table 1) and all are potent T cell mitogens with half maximum stimulation values as low as 0·1 pg/ml. The SAg family also includes the S. aureus toxic shock syndrome toxin (TSST) which is the causative agent in toxic shock syndrome [18]. Twelve SAgs have been identified in Group A Streptococci (GAS), predominantly but not exclusively produced by S. pyogenes. These are the streptococcal pyrogenic exotoxins (SPEs) A, C, G-M, the streptococcal superantigen (SSA) and the streptococcal mitogenic exotoxin (SMEZ) 1 and 2. Many new SAgs have been identified by screening the completed S. pyogenes genomes; serotypes M1 (Oklahoma University, USA), M3 and M18 (Rocky Mountain Laboratories, NIH, USA) with conserved sequence motifs [10–13]. The sudden explosion of new superantigen sequences has resulted in confusing nomenclature where some sequences have been given two different names. For example, SPE-K identified in a serotype M3 strain from the United States is identical to SPE-L found in an M3 strain from Japan and an M89 strain from New Zealand [10,19,20]. The superantigen gene spe-l found in an M18 strain from the United States is identical to a gene named spe-m found in New Zealand [13,20]. For the purposes of this review, spe-m* is the g

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2249.2003.02203.x

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 440

Metadata

Authors
PROFT, T., & FRASER, J. D.
Venue
Clinical and Experimental Immunology
Published
2003-08-19
Volume
133
Issue
3
Pages
299-306
ISSN
  • 0009-9104 (ISSN-L)
  • 1365-2249
OpenAlex
W3188209924
Cited by
440
References
48
FWCI
8.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bacterial superantigens. https://app.cochat.ai/papers/10.1046/j.1365-2249.2003.02203.x
The paper
PROFT, T., & FRASER, J. D. (2003). Bacterial superantigens. Clinical and Experimental Immunology. https://doi.org/10.1046/j.1365-2249.2003.02203.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.